Development of virus-like particles for diagnostic and prophylactic biomedical applications

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 7, Issue 5, 2015, Pages 722-735

  Schwarz, Benjamin ^a   Douglas, Trevor ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; MAGNETIC RESONANCE IMAGING; MEDICAL APPLICATIONS; NANOPARTICLES; SCAFFOLDS (BIOLOGY); VIRUSES;

ANTIGEN PRESENTATION; BIOMEDICAL APPLICATIONS; DIAGNOSTIC IMAGING; INNATE IMMUNE SYSTEMS; MAGNETIC RESONANCE IMAGING CONTRAST AGENTS; NANOSCALE ARCHITECTURES; SYNTHETIC STRATEGIES; VIRUS-LIKE PARTICLES;

IMMUNE SYSTEM;

GADOLINIUM; NANOPARTICLE; VIRUS VACCINE; CONTRAST MEDIUM;

ANTIGEN PRESENTATION; ARTICLE; BACTERIOPHAGE; BIOMEDICINE; DRUG DESIGN; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOID TISSUE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLANT; PRIORITY JOURNAL; VIRUS; VIRUS LIKE AGENT; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; HUMAN; IMMUNITY; MEDICAL TECHNOLOGY; PROCEDURES; VIRION;

ANIMALS; BIOMEDICAL TECHNOLOGY; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; IMMUNITY; VIRION;

EID: 84937818268     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1336     Document Type: Article

References (64)

1. Prugnolle F, Manica A, Charpentier M, Guégan JF, Guernier V, Balloux F. Pathogen-driven selection and worldwide HLA class I diversity. Curr Biol 2005, 15:1022-1027.
2. Woolhouse MEJ, Webster JP, Domingo E, Charlesworth B, Levin BR. Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet 2002, 32:569-577.
3. Suttle CA. Viruses in the sea. Nature 2005, 437:356-361.
4. Lucon J, Qazi S, Uchida M, Bedwell GJ, LaFrance B, Prevelige PE Jr, Douglas T. Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading. Nat Chem 2012, 4:781-788.
5. Patel MV, Chen FJ. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions, 2001. Available at: http://www.google.com/patents/US6248363. (Accessed June, 25 2014).
6. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009, 17:2950-2962.
7. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005, 23:1418-1423.
8. Slowing II, Vivero-Escoto JL, Wu C-W, Lin VSY. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008, 60:1278-1288.
9. Liepold LO, Abedin MJ, Buckhouse ED, Frank JA, Young MJ, Douglas T. Supramolecular protein cage composite MR contrast agents with extremely efficient relaxivity properties. Nano Lett 2009, 9:4520-4526.
10. Mulder WJM, Strijkers GJ, van Tilborg GAF, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006, 19:142-164.
11. Ananta JS, Godin B, Sethi R, Moriggi L, Liu X, Serda RE, Krishnamurthy R, Muthupillai R, Bolskar RD, Helm L, et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nano 2010, 5:815-821.
12. Allen M, Bulte JWM, Liepold L, Basu G, Zywicke HA, Frank JA, Young M, Douglas T. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn Reson Med 2005, 54:807-812.
13. Bruckman MA, Hern S, Jiang K, Flask CA, Yu X, Steinmetz NF. Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents. J Mater Chem B 2013, 1:1482-1490.
14. Liepold L, Anderson S, Willits D, Oltrogge L, Frank JA, Douglas T, Young M. Viral capsids as MRI contrast agents. Magn Reson Med 2007, 58:871-879.
15. Anderson EA, Isaacman S, Peabody DS, Wang EY, Canary JW, Kirshenbaum K. Viral nanoparticles donning a paramagnetic coat: conjugation of MRI contrast agents to the MS2 capsid. Nano Lett 2006, 6:1160-1164.
16. Prasuhn JDE, Yeh RM, Obenaus A, Manchester M, Finn MG. Viral MRI contrast agents: coordination of Gd by native virions and attachment of Gd complexes by azide-alkyne cycloaddition. Chem Commun 2007:1269-1271. doi: 10.1039/B615084E.
17. Pokorski JK, Breitenkamp K, Liepold LO, Qazi S, Finn MG. Functional virus-based polymer-protein nanoparticles by atom transfer radical polymerization. J Am Chem Soc 2011, 133:9242-9245.
18. Rocklage SM, Worah D, Kim SH. Metal ion release from paramagnetic chelates: what is tolerable? Magn Reson Med 1991, 22:216-221; discussion 229-232.
19. Klug A. The tobacco mosaic virus particle: structure and assembly. Philos Trans R Soc Lond B Biol Sci 1999, 354:531-535.
20. Kim R, Kim KK, Yokota H, Kim SH. Small heat shock protein of Methanococcus jannaschii, a hyperthermophile. Proc Natl Acad Sci U S A 1998, 95:9129-9133.
21. Hovlid ML, Lau JL, Breitenkamp K, Higginson CJ, Laufer B, Manchester M, Finn MG. Encapsidated atom-transfer radical polymerization in Qβ virus-like nanoparticles. ACS Nano 2014, 8:8003-8014.
22. Qazi S, Uchida M, Usselman R, Shearer R, Edwards E, Douglas T. Manganese (III) porphyrins complexed with P22 virus-like particles as T 1-enhanced contrast agents for magnetic resonance imaging. J Biol Inorg Chem 2014, 19:237-246.
23. Terashima M, Uchida M, Kosuge H, Tsao PS, Young MJ, Conolly SM, Douglas T, McConnell MV. Human ferritin cages for imaging vascular macrophages. Biomaterials 2011, 32:1430-1437.
24. Uchida M, Flenniken ML, Allen M, Willits DA, Crowley BE, Brumfield S, Willis AF, Jackiw L, Jutila M, Young MJ, et al. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J Am Chem Soc 2006, 128:16626-16633.
25. Uchida M, Klem MT, Allen M, Suci P, Flenniken M, Gillitzer E, Varpness Z, Liepold LO, Young M, Douglas T. Biological containers: protein cages as multifunctional nanoplatforms. Adv Mater 2007, 19:1025-1042.
26. Vymazal J, Brooks RA, Zak O, McRill C, Shen C, Chiro GD. T1 and t2 of ferritin at different field strengths: effect on mri. Magn Reson Med 1992, 27:368-374.
27. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
28. Grgacic EVL, Anderson DA. Virus-like particles: Passport to immune recognition. Methods 2006, 40:60-65.
29. Koudelka KJ, Rae CS, Gonzalez MJ, Manchester M. Interaction between a 54-kilodalton mammalian cell surface protein and cowpea mosaic virus. J Virol 2007, 81:1632-1640.
30. Koudelka KJ, Destito G, Plummer EM, Trauger SA, Siuzdak G, Manchester M. Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin. PLoS Pathog 2009, 5:e1000417.
31. Steinmetz NF, Cho CF, Ablack A, Lewis JD, Manchester M. Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells. Nanomedicine (Lond) 2011, 6:351-364.
32. Singh P, Destito G, Schneemann A, Manchester M. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnol 2006, 4:1-11.
33. Flenniken ML, Willits DA, Harmsen AL, Liepold LO, Harmsen AG, Young MJ, Douglas T. Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem Biol 2006, 13:161-170.
34. Kitagawa T, Kosuge H, Uchida M, Dua MM, Iida Y, Dalman RL, Douglas T, McConnell MV. RGD-conjugated human ferritin nanoparticles for imaging vascular inflammation and angiogenesis in experimental carotid and aortic disease. Mol Imaging Biol 2012, 14:315-324.
35. Uchida M, Willits DA, Muller K, Willis AF, Jackiw L, Jutila M, Young MJ, Porter AE, Douglas T. Intracellular distribution of macrophage targeting ferritin-iron oxide nanocomposite. Adv Mater 2009, 21:458-462.
36. Garcea RL, Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol 2004, 15:513-517.
37. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003, 11:438-444.
38. Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity 2007, 27:370-383.
39. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006, 7:131-137.
40. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
41. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
42. Randall TD. Chapter 7-Bronchus-associated lymphoid tissue (BALT): structure and function. In: Sidonia F, Andrea C, eds. Advances in Immunology, vol. 107. San Diego, CA: Academic Press; 2010, 187-241.
43. Wiley JA, Richert LE, Swain SD, Harmsen A, Barnard DL, Randall TD, Jutila M, Douglas T, Broomell C, Young M. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One 2009, 4:e7142.
44. Richert LE, Harmsen AL, Rynda-Apple A, Wiley JA, Servid AE, Douglas T, Harmsen AG. Inducible bronchus-associated lymphoid tissue (iBALT) synergizes with local lymph nodes during antiviral CD4+ T cell responses. Lymphat Res Biol 2013, 11:196-202.
45. Walkey CD, Olsen JB, Guo H, Emili A, Chan WCW. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 2011, 134:2139-2147.
46. Zabel F, Kündig TM, Bachmann MF. Virus-induced humoral immunity: on how B cell responses are initiated. Curr Opin Virol 2013, 3:357-362.
47. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25:3871-3878.
48. Lua LHL, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg APJ. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 2014, 111:425-440.
49. Richert LE, Servid AE, Harmsen AL, Rynda-Apple A, Han S, Wiley JA, Douglas T, Harmsen AG. A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine 2012, 30:3653-3665.
50. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010, 363:2036-2044.
51. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531-569.
52. Ekiert DC, Bhabha G, Elsliger M-A, Friesen RHE, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
53. Kanekiyo M, Wei C-J, Yassine HM, McTamney PM, Boyington JC, Whittle JRR, Rao SS, Kong W-P, Wang L, Nabel GJ. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499:102-106.
54. Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, Yao Q. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother (Hagerstown, Md) 2009, 32:118-128.
55. Ichinohe T, Tamura S-I, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Takahashi H, Sawa H. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 2007, 196:1313-1320.
56. Bachmann MF, Kündig TM, Freer G, Li Y, Kang CY, Bishop DH, Hengartner H, Zinkernagel RM. Induction of protective cytotoxic T cells with viral proteins. Eur J Immunol 1994, 24:2228-2236.
57. Storni T, Lechner F, Erdmann I, Bächi T, Jegerlehner A, Dumrese T, Kündig TM, Ruedl C, Bachmann MF. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 2002, 168:2880-2886.
58. Parent MA, Berggren KN, Kummer LW, Wilhelm LB, Szaba FM, Mullarky IK, Smiley ST. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun 2005, 73:7304-7310.
59. An P, Digard P. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 2002, 83:723-734.
60. Patterson DP, Rynda-Apple A, Harmsen AL, Harmsen AG, Douglas T. Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano 2013, 7:3036-3044.
61. Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, Speiser DE, Romero P. Virus-like particles induce robust human T-helper cell responses. Eur J Immunol 2012, 42:330-340.
62. Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 2010, 33:848-858.
63. Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, Willers J, Geldhof C, Prior JO, Kündig TM, et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8 + T-cell responses in melanoma patients. Eur J Immunol 2012, 42:3049-3061.
64. Zolnik BS, González-Fernández Á, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology 2010, 151:458-465.